TG Therapeutics reported $85.9M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Alaunos Therapeutics USD -952K 60K Jun/2026
Amgen USD 4.68B 65M Sep/2026
Ardelyx USD -10.39M 20.29M Jun/2026
Arrowhead Research USD -154.34M 13.08M Jun/2026
Bayer EUR 129M 626M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Curis USD -11.52M 3.64M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Novartis USD 5.14B 411M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026
Verastem USD -44.9M 3.42M Mar/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026